8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): July 10, 2013

Sagent Pharmaceuticals, Inc.

(Exact name of registrant as specified in its charter)

Commission File Number: 1-35144

Delaware	98-0536317
(State or other jurisdiction of incorporation)	(IRS Employer Identification No.)

1901 N. Roselle Road, Suite 700, Schaumburg, Illinois 60195

(Address of principal executive offices, including zip code)

(847) 908-1600

(Registrant’s telephone number, including area code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

On July 10, 2013, the Board of Directors of Sagent Pharmaceuticals, Inc. (the “Company”) appointed Michael Fekete as a Class I director of the Company, effective immediately. Mr. Fekete has been designated to serve on the Company’s Audit and Compensation Committees.

Mr. Fekete was not selected pursuant to any arrangement or understanding between him and any other person. Mr. Fekete has no family relationships with any of the Company’s directors or executive officers. There have been no related person transactions between the Company and Mr. Fekete reportable under Item 404(a) of Regulation S-K.

Mr. Fekete will receive the standard compensation received by non-employee directors. These compensation arrangements are described in the Company’s 2013 Proxy Statement, filed with the SEC on April 30, 2013.

Item 8.01 Other Events

On July 11, 2013, the Company issued a press release announcing the appointment of Mr. Fekete described in Item 5.02 above. A copy of that press release is furnished herewith as Exhibit 99.1.

Item 9.01. Financial Statements and Exhibits.

(d) The following exhibit is being furnished with this Current Report on Form 8-K.

Exhibit Number	Description
99.1	Sagent Pharmaceuticals, Inc. Press Release, dated July 11, 2013.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

		SAGENT PHARMACEUTICALS, INC.
Date: July 11, 2013		/s/ MICHAEL LOGERFO
	Name:	Michael Logerfo
	Title:	Executive Vice President, Chief Legal Officer and Corporate Secretary

EX-99.1

Exhibit 99.1

For Immediate Release

SAGENT CONTACT:

Jonathon Singer

jsinger@sagentpharma.com

(847) 908-1605

Sagent Pharmaceuticals Appoints Michael Fekete to its Board of Directors

SCHAUMBURG, Ill., July 11, 2013 – Sagent Pharmaceuticals, Inc. (NASDAQ: SGNT), a leader of specialty pharmaceutical products with an emphasis on the injectable market, today announced that its Board of Directors has expanded the size of the Board from five to six members and appointed Michael Fekete as a Class I Director effective July 10, 2013.

“We are delighted to have Mike join the Company’s Board of Directors,” said Jeffrey M. Yordon, founder, chief executive officer and chairman of the board of Sagent. “Mike brings a wealth of experience in advising healthcare companies and has specific knowledge of the generic injectable pharmaceutical industry. Mike worked with Sagent as an advisor in connection with our successful initial public offering and Mike’s experience and skill set will be particularly valuable to us as we continue to drive our growth. We look forward to his contribution to the Board of Directors and his involvement with senior management of the Company.”

Mr. Fekete, 49, is an independent corporate advisor specializing in capital markets, mergers and acquisitions and general corporate strategy with over 25 years of professional experience advising public and private companies, primarily in the healthcare sector. He began his career in investment banking in 1986 and has worked for a number of firms, including Wells Fargo, Wachovia Corporation, CIBC World Markets, Oppenheimer & Co. and L.F. Rothschild & Co., Inc. Mr. Fekete is a director of DFB Pharmaceuticals, a privately held specialty pharmaceutical company and of Symetis SA, a privately held company developing minimally invasive heart valve replacement therapies for patients suffering from heart valve diseases. Mr. Fekete earned a bachelor’s degree of science in business administration from the Pennsylvania State University.

About Sagent Pharmaceuticals

Sagent Pharmaceuticals, Inc., founded in 2006, is a specialty pharmaceutical company focused on developing, manufacturing, sourcing and marketing pharmaceutical products, with a specific emphasis on injectable products. Sagent has created a unique, global network of resources, comprised of rapid development capabilities, sophisticated manufacturing and innovative drug-delivery technologies, quickly yielding an extensive portfolio of pharmaceutical products that fulfills the evolving needs of patients.